Wire · opportunities
Regeneron Gained FDA Approval for RNAi Treatment Livsayis
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 22 November 2026 · Fusion42 review
Regeneron received FDA approval for Livsayis, an RNA interference therapy for generalized myasthenia gravis, marking the first approved treatment for this chronic autoimmune neuromuscular disorder with a quarterly dosing schedule that offers a competitive advantage.
This Wire brief sits within Fusion42's coverage of Biotech.
◆ ◆ The Wire takeaway
You have a new approval path to challenge chronic autoimmune diseases with less frequent dosing while beating weekly competitors. RNAi therapies like Livsayis now set a fresh benchmark for biotech drug regimens.
◆ Coverage
1 source · 21 Nov 2026
◆ Related on Wire
◆ Topics